ASTH Earnings Q2 2026: Full Analysis of Astrana Health's Quarterly Results

Revenue Performance and Top-Line Growth

Astrana Health reported total revenue of [Q2_REVENUE] for the second quarter of 2026, compared to analyst consensus estimates of [CONSENSUS_REVENUE] (per analyst estimates compiled by Bloomberg). This result represented a [YOY_REVENUE_GROWTH]% change year-over-year from the same quarter in 2025.

The company's revenue trajectory reflects its ongoing strategy of expanding its managed care footprint and deepening relationships with healthcare providers across its core markets. Astrana Health has historically concentrated its operations in California and Texas, with increasing penetration into additional states through both organic growth and strategic acquisitions.

Top-line performance was influenced by several factors, including membership growth in its capitated care model, changes in per-member-per-month (PMPM) rates, and the integration of previously acquired businesses. Investors should note that revenue recognition in value-based care models can be lumpy due to risk-adjustment true-ups and retroactive premium adjustments from payers.

Earnings Per Share and Profitability Metrics

Astrana Health posted GAAP earnings per share (EPS) of [GAAP_EPS] for Q2 2026, while adjusted EPS came in at [ADJ_EPS]. The Wall Street consensus had projected adjusted EPS of [CONSENSUS_EPS] (according to analyst estimates from Refinitiv), meaning the company [BEAT_OR_MISSED] expectations by [EPS_DIFFERENCE].

GAAP net income for the quarter was [NET_INCOME], reflecting the impact of non-cash items such as stock-based compensation, amortization of acquired intangible assets, and any one-time charges related to acquisitions or restructuring activities. Adjusted net income, which strips out these items, totaled [ADJ_NET_INCOME].

The difference between GAAP and adjusted figures is particularly noteworthy for Astrana Health, as the company has been an active acquirer in recent years. Amortization charges from acquired provider networks and technology platforms can significantly depress GAAP earnings relative to the company's underlying operational performance. Investors evaluating how to analyze healthcare earnings reports should pay close attention to these adjustments.

Margin Analysis: Operating and Adjusted EBITDA

Astrana Health's operating margin for Q2 2026 came in at [OPERATING_MARGIN]%, compared to [PRIOR_YEAR_OPERATING_MARGIN]% in Q2 2025. This [IMPROVEMENT_OR_DECLINE] reflects the company's ongoing efforts to scale its care delivery platform while managing medical costs within its capitated arrangements.

Adjusted EBITDA for the quarter was [ADJ_EBITDA], representing an adjusted EBITDA margin of [EBITDA_MARGIN]%. This metric is widely considered one of the most important profitability indicators for value-based care companies, as it captures the core economics of managing patient populations under risk-bearing contracts.

Medical Cost Ratio Trends

The medical cost ratio (MCR) — a critical metric for any company bearing healthcare risk — stood at [MCR]% during Q2 2026. This figure measures the percentage of premium revenue consumed by medical expenses and is a key determinant of Astrana Health's profitability under its capitated contracts.

Seasonal patterns can significantly affect MCR from quarter to quarter. Q2 results are typically influenced by the completion of annual wellness visits, updated risk-adjustment data submissions, and utilization patterns that may differ from Q1's typically lower utilization levels. Investors should compare MCR trends across multiple quarters rather than drawing conclusions from a single period.

Segment Breakdown and Business Unit Performance

Care Partners Segment

Astrana Health's Care Partners segment, which encompasses the company's managed care and risk-bearing operations, generated revenue of [CARE_PARTNERS_REVENUE] during Q2 2026. This segment is the core of Astrana's business model, where the company partners with independent physicians to manage patient populations under value-based contracts with health plans.

Total lives under management reached [TOTAL_LIVES] at the end of Q2 2026, reflecting [LIVES_GROWTH] compared to the prior-year period. Growth in managed lives is a leading indicator of future revenue expansion and demonstrates the company's ability to attract physician partners to its platform.

Care Delivery Segment

The Care Delivery segment, which includes Astrana Health's directly operated clinics and ancillary services, reported revenue of [CARE_DELIVERY_REVENUE]. This segment complements the Care Partners business by providing clinical infrastructure that supports population health management.

Operating performance in Care Delivery is influenced by patient visit volumes, payer mix, and the company's ability to close gaps in care — an activity that not only improves patient outcomes but also supports higher risk-adjustment scores under Medicare Advantage and other capitated programs.

Care Enablement Segment

Astrana Health's Care Enablement segment, which houses the company's technology platform and administrative services, contributed revenue of [CARE_ENABLEMENT_REVENUE]. This segment provides the data analytics, claims processing, and practice management tools that underpin the entire Astrana ecosystem.

Investors interested in healthcare technology stocks and value-based care trends should monitor this segment closely, as its scalability is central to Astrana Health's long-term margin expansion thesis.

Balance Sheet and Cash Flow Highlights

As of the end of Q2 2026, Astrana Health reported total cash and cash equivalents of [CASH_POSITION], with total debt of [TOTAL_DEBT]. The company's net debt-to-adjusted EBITDA ratio stood at [LEVERAGE_RATIO]x, which positions it [FAVORABLY_OR_CAUTIOUSLY] relative to its peers in the healthcare services space.

Operating cash flow for the quarter totaled [OPERATING_CASH_FLOW], while free cash flow came in at [FREE_CASH_FLOW]. Cash flow generation is a critical consideration for Astrana Health investors, as the company must balance reinvestment in growth — including potential acquisitions and technology development — with maintaining financial flexibility.

Capital expenditures during Q2 2026 were [CAPEX], directed primarily toward clinic buildouts, technology infrastructure, and integration of acquired businesses. The company's capital allocation strategy continues to prioritize growth investments over shareholder returns such as dividends or buybacks at this stage of its maturity.

Management Guidance and Forward Outlook

During the Q2 2026 earnings call, Astrana Health's management team provided updated guidance for the full fiscal year 2026 (according to the company's earnings press release and conference call transcript). Key guidance figures included:

• Full-year revenue: [FY_REVENUE_GUIDANCE_LOW] to [FY_REVENUE_GUIDANCE_HIGH]
• Adjusted EBITDA: [FY_EBITDA_GUIDANCE_LOW] to [FY_EBITDA_GUIDANCE_HIGH]
• Adjusted EPS: [FY_EPS_GUIDANCE_LOW] to [FY_EPS_GUIDANCE_HIGH]
• Total managed lives: [FY_LIVES_GUIDANCE]

Management [RAISED_MAINTAINED_OR_LOWERED] its full-year guidance relative to the outlook provided during Q1 2026. Commentary on the earnings call highlighted [KEY_GUIDANCE_THEMES], including trends in Medicare Advantage enrollment, Medicaid redetermination impacts, and the competitive landscape for physician partnerships.

CEO and founder Brandon Sim has consistently emphasized Astrana Health's mission to empower physicians through value-based care. During the Q2 call, management also addressed [ADDITIONAL_TOPICS] such as regulatory developments, payer contract renewals, and the company's acquisition pipeline.

Analyst Reactions and Market Response

Following the release of ASTH earnings for Q2 2026, shares of Astrana Health [ROSE_OR_FELL] [STOCK_MOVEMENT]% in [PRE_MARKET_OR_AFTER_HOURS] trading. The stock's reaction reflects the market's interpretation of both the quarterly results and the forward guidance relative to prior expectations.

Sell-side analysts covering Astrana Health offered [MIXED_OR_CONSENSUS] reactions to the results. The consensus price target stood at [CONSENSUS_PT] following the earnings release, implying [UPSIDE_OR_DOWNSIDE]% from the stock's current trading price of [CURRENT_PRICE] (per Bloomberg consensus data). ASTH currently trades at a forward price-to-earnings ratio of [PE_RATIO]x and an EV/EBITDA multiple of [EV_EBITDA]x.

Key themes from analyst commentary included [ANALYST_THEMES], with particular focus on the sustainability of membership growth, the trajectory of medical cost ratios, and Astrana Health's competitive positioning relative to other value-based care platforms such as agilon health, Privia Health, and Oak Street Health (now part of CVS Health).

What ASTH Earnings Q2 2026 Mean for Investors

Astrana Health's Q2 2026 earnings report provides important data points for both current shareholders and prospective investors evaluating the stock. The results should be assessed in the context of several broader considerations:

• Secular tailwinds in value-based care: The ongoing shift from fee-for-service to value-based payment models continues to create a large addressable market for companies like Astrana Health.
• Integration execution: Astrana Health's acquisition-driven growth strategy requires disciplined integration to realize expected synergies and maintain care quality.
• Regulatory environment: Changes to Medicare Advantage rate structures, risk-adjustment methodologies, and Medicaid policies can materially impact Astrana's economics.
• Competitive dynamics: The value-based care enablement space is increasingly competitive, and physician groups have multiple platform options to consider.

Investors looking to build a comprehensive view of Astrana Health should review the full 10-Q filing with the SEC, listen to the earnings conference call webcast, and consider how Q2 results fit within the company's multi-year growth trajectory. For additional context, explore our guide to evaluating value-based care companies.

As always, quarterly earnings represent just one snapshot in time. Long-term investors should focus on the durability of Astrana Health's competitive moat, its ability to attract and retain physician partners, and the scalability of its technology platform as the primary drivers of shareholder value creation.